Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m + diethylenetriaminepentaacetic acid
- Development stage
- Unknown
- Lead developer
- Jubilant DraxImage
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Inhalation
01
Overview
Technetium-99m + diethylenetriaminepentaacetic acid (commonly referred to as Tc‑99m DTPA or technetium tc 99m pentetate) is a radiopharmaceutical used in nuclear medicine for diagnostic imaging. It consists of the radioisotope technetium‑99m chelated with diethylenetriaminepentaacetic acid (DTPA). The compound is primarily used for renal imaging to assess glomerular filtration rate, but it is also indicated for brain and lung imaging. After intravenous administration, it is distributed in the vascular compartment and cleared exclusively by glomerular filtration, making it useful for direct measurement of kidney function. When administered via inhalation, it deposits on alveolar epithelium and enables assessment of lung ventilation. The agent accumulates in areas with altered blood-brain barrier or neovascularity during brain scans[1][2][4][5][7].
- Brand names
- Draximage DTPAAn-DTPAMPI DTPA
- Other names
- technetium (99mTc) pentetic acidTc 99m-diethylenetriaminepentaacetic acidTc99m-diethylenetriaminepentaacetic acidTc-99m-diethylenetriaminepentaacetic acidTc 99m pentetateTc99m pentetateTc-99m pentetate
Beyond the preview
Go deeper on technetium-99m + diethylenetriaminepentaacetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m + diethylenetriaminepentaacetic acid.